×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SLDB – solid biosciences inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SLDB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/15
01:01 pm
sldb
JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success [Yahoo! Finance]
Low
Report
JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success [Yahoo! Finance]
1/14
12:30 pm
sldb
Solid Biosciences (NASDAQ:SLDB) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.
Low
Report
Solid Biosciences (NASDAQ:SLDB) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.
1/14
03:53 am
sldb
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101 [Yahoo! Finance]
High
Report
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101 [Yahoo! Finance]
1/13
04:15 pm
sldb
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101
High
Report
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101
1/12
04:15 pm
sldb
Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia
Medium
Report
Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia
1/12
08:27 am
sldb
Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia [Yahoo! Finance]
Low
Report
Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia [Yahoo! Finance]
1/12
08:05 am
sldb
Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia
Medium
Report
Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia
1/6
08:00 am
sldb
Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Date
Time
Action
From
To
Firm
Impact
%Chg
12/17
08:45 am
Reiterates
Market Outperform
Market Outperform
Citigroup Inc.
High
Report
-10.5%
Date
Time
Symbol
Headline
Impact
1/13
05:03 pm
sldb
Form 4 Solid Biosciences Inc. For: Jan 09 Filed by: Tan Kevin
High
Report
Form 4 Solid Biosciences Inc. For: Jan 09 Filed by: Tan Kevin
1/13
05:01 pm
sldb
Form 144 Solid Biosciences Inc. Filed by: Tan Kevin
High
Report
Form 144 Solid Biosciences Inc. Filed by: Tan Kevin
1/7
04:05 pm
sldb
Form 4 Solid Biosciences Inc. For: Jan 02 Filed by: SMITH IAN F
Medium
Report
Form 4 Solid Biosciences Inc. For: Jan 02 Filed by: SMITH IAN F
1/6
06:52 pm
sldb
Form 4 Solid Biosciences Inc. For: Jan 03 Filed by: Ganot Ilan
Medium
Report
Form 4 Solid Biosciences Inc. For: Jan 03 Filed by: Ganot Ilan
12/4
04:22 pm
sldb
Form 4 Solid Biosciences Inc. For: Dec 02 Filed by: Howton David T
Low
Report
Form 4 Solid Biosciences Inc. For: Dec 02 Filed by: Howton David T
12/4
04:21 pm
sldb
Form 4 Solid Biosciences Inc. For: Dec 02 Filed by: Cumbo Alexander
Low
Report
Form 4 Solid Biosciences Inc. For: Dec 02 Filed by: Cumbo Alexander
12/4
04:19 pm
sldb
Form 4 Solid Biosciences Inc. For: Dec 02 Filed by: Hanrahan Jessie
Low
Report
Form 4 Solid Biosciences Inc. For: Dec 02 Filed by: Hanrahan Jessie
12/4
04:17 pm
sldb
Form 4 Solid Biosciences Inc. For: Dec 02 Filed by: Herzich Paul
Low
Report
Form 4 Solid Biosciences Inc. For: Dec 02 Filed by: Herzich Paul
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
7/26
Solid Biosciences Announces $60 Million Private Placement with New and Existing Investors
34.4%
8/16 Solid Biosciences Inc (NASDAQ: SLDB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $10.00 price target on the stock. 33.5%
8/14 Solid Biosciences Reports Second Quarter 2019 Financial Results and Provides Business Update 23.8%
5/14 Solid Biosciences Inc (NASDAQ: SLDB) was downgraded by analysts at Chardan Capital from a "buy" rating to a "neutral" rating. They now have a $7.50 price target on the stock. 18.9%
10/11 Solid Biosciences Inc (NASDAQ: SLDB) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock. 11.2%
9/20 Solid Biosciences Inc (NASDAQ: SLDB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock. 11.2%
10/16 SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Solid Biosciences Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors 10.7%
7/29 Form 4 Solid Biosciences Inc. For: Jul 25 Filed by: Ganot Ilan 9.0%
8/27 Solid Biosciences Looks Like An Obvious Sell [Seeking Alpha] 8.7%
11/12 Solid Biosciences Inc (NASDAQ: SLDB) had its price target lowered by analysts at Credit Suisse Group AG from $6.00 to $2.00. They now have a "hold" rating on the stock. 7.4%
8/16 Solid Biosciences Inc (NASDAQ: SLDB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $10.00 price target on the stock. 33.5%
8/14 Solid Biosciences Reports Second Quarter 2019 Financial Results and Provides Business Update 23.8%
5/14 Solid Biosciences Inc (NASDAQ: SLDB) was downgraded by analysts at Chardan Capital from a "buy" rating to a "neutral" rating. They now have a $7.50 price target on the stock. 18.9%
10/11 Solid Biosciences Inc (NASDAQ: SLDB) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock. 11.2%
9/20 Solid Biosciences Inc (NASDAQ: SLDB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock. 11.2%
10/16 SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Solid Biosciences Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors 10.7%
7/29 Form 4 Solid Biosciences Inc. For: Jul 25 Filed by: Ganot Ilan 9.0%
8/27 Solid Biosciences Looks Like An Obvious Sell [Seeking Alpha] 8.7%
11/12 Solid Biosciences Inc (NASDAQ: SLDB) had its price target lowered by analysts at Credit Suisse Group AG from $6.00 to $2.00. They now have a "hold" rating on the stock. 7.4%
TOP News Decliners
11/12
Solid Biosciences Provides SGT-001 Program Update
-74.4%
5/13 Q1/2019 3/31/2019 EPS -0.850 ZacksConsensus -0.610 ActVsEst (0.240) - Miss -28.6%
3/13 Form 4 Solid Biosciences Inc. For: Mar 11 Filed by: Ziolkowski Jennifer Lynn -21.1%
12/18 Solid Biosciences stock are up on DMD study news [MarketWatch] -20.1%
1/9 Form 8-K Solid Biosciences Inc. For: Jan 07 -14.6%
3/23 Solid Biosciences Inc (NASDAQ: SLDB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock. -9.3%
7/26 Form 8-K Solid Biosciences Inc. For: Jul 25 -9.2%
3/20 Solid Biosciences Inc (NASDAQ: SLDB) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -6.9%
8/29 Solid Biosciences Inc (NASDAQ: SLDB) was downgraded by analysts at Citigroup Inc from a "neutral" rating to a "sell" rating. They now have a $6.00 price target on the stock. -5.4%
7/31 Form D Solid Biosciences Inc. -5.3%
5/13 Q1/2019 3/31/2019 EPS -0.850 ZacksConsensus -0.610 ActVsEst (0.240) - Miss -28.6%
3/13 Form 4 Solid Biosciences Inc. For: Mar 11 Filed by: Ziolkowski Jennifer Lynn -21.1%
12/18 Solid Biosciences stock are up on DMD study news [MarketWatch] -20.1%
1/9 Form 8-K Solid Biosciences Inc. For: Jan 07 -14.6%
3/23 Solid Biosciences Inc (NASDAQ: SLDB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock. -9.3%
7/26 Form 8-K Solid Biosciences Inc. For: Jul 25 -9.2%
3/20 Solid Biosciences Inc (NASDAQ: SLDB) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -6.9%
8/29 Solid Biosciences Inc (NASDAQ: SLDB) was downgraded by analysts at Citigroup Inc from a "neutral" rating to a "sell" rating. They now have a $6.00 price target on the stock. -5.4%
7/31 Form D Solid Biosciences Inc. -5.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: